Table 3.
Pharmacokinetic parameter estimates of 111In-DOTA-EB-cRGDfK and 111In-DOTA-cRGDfK after intravenous administration in U-87 MG tumor-bearing mice.
| Parameter | Unit | 111In-DOTA-EB-cRGDfK | 111In-DOTA-cRGDfK |
|---|---|---|---|
| T1/2λz | h | 77.3 | 17.2 |
| Cmax | % ID/mL | 13.1 | 3.74 |
| Cl | mL/h | 0.426 | 12.9 |
| AUC(0→∞) | % ID/mL × h | 242 | 4.02 |
| MRT(0→∞) | h | 77.2 | 10.3 |
Calculated with the WinNonlin program for a noncompartmental model. T1/2λz, terminal half-life; Cmax, maximum concentration; Cl, total body clearance; AUC, area under curve; MRT, mean residence time.